Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 12/20 | 0.82 |
| ▸ | AVPR1B | P47901 | 9/20 | 0.82 |
| ▸ | AVPR2 | P30518 | 8/20 | 0.82 |
| ▸ | OXTR | P30559 | 7/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.77 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Felypressin SCHEMBL1650172 | 1.00 | AVPR1A (0.82) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Felypressin SCHEMBL31138866 | 1.00 | AVPR1A (0.82) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Felypressin SCHEMBL361197 | 1.00 | AVPR1A (0.82) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Felypressin SCHEMBL4405496 | 0.98 | AVPR1A (0.79) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Lypressin SCHEMBL1650587 | 0.97 | OXTR (0.87) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Lypressin SCHEMBL33287 | 0.97 | OXTR (0.87) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Felypressin SCHEMBL5199973 | 0.97 | AVPR1A (0.77) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Lypressin SCHEMBL29471105 | 0.96 | OXTR (0.84) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Ornipressin SCHEMBL1650220 | 0.95 | AVPR1A (0.88) | AVPR1AAVPR1BAVPR2OXTRTBXA2R | |
| Ornipressin SCHEMBL296322 | 0.95 | AVPR1A (0.88) | AVPR1AAVPR1BAVPR2OXTRTBXA2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1779 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633737-A1 | USES OF AVPR1A AGONISTS | Viage Therapeutics Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250255755-A1 | WOUND HEALING DEVICE AND METHODS FOR WOUND HEALING | SINUS CLEAR INNOVATIONS LLC (US) | 2025-08-14 | — | — | US | claimed |
| CN-120081915-A | Construction method and application of Crimedes-Congo hemorrhagic fever virus (CCHFV) virus-like particle (VLP) | 湖北江夏实验室 | 2025-06-03 | — | — | CN | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| CN-120012326-A | Equivalent modeling method and device for power distribution network | 国网河北省电力有限公司电力科学研究院 | 2025-05-16 | — | — | CN | claimed |
| CN-119876035-A | Method for constructing tumor organoid and fibroblast high-flux medicine sieve model | 南昌大学 | 2025-04-25 | — | — | CN | claimed |
| CN-119523450-A | Cardiac output estimation method based on catheter pump | 苏州心岭迈德医疗科技有限公司 | 2025-02-28 | — | — | CN | claimed |
| US-20240293345-A1 | COMBINATIONS OF LOCAL ANESTHETICS FOR IMPROVED PAIN RELIEF | PHARMAVAX AS (NO) | 2024-09-05 | — | — | US | claimed |
| WO-2024130011-A1 | USES OF AVPR1A AGONISTS | VIAGE THERAPEUTICS INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20240139027-A1 | DIAGNOSTIC METHODS AND APPARATUS | FORSIGHT VISION4, INC. | 2024-05-02 | — | — | US | claimed |
| WO-2004014411-A1 | NASAL PEPTIDE PHARMACEUTICAL FORMULATION | THERAPICON SRL (IT) | 2004-02-19 | — | — | WO | claimed |
| US-20030125528-A1 | Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon | HAY BRUCE A (US) | 2003-07-03 | — | — | US | claimed |
| CN-1305490-A | Improved processing for preparing schift base adducts of amines with i(o)-hydroxy aldehydes and compositions of matter based thereon | PFIZER PROD INC (US) | 2001-07-25 | — | — | CN | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
| EP-0938338-A1 | CARRIER COMPOSITION FOR INFLUENCING THE TIGHT JUNCTION PERMEABILITY | Ghyssaert, Joris Rosa Michael (BE) | 1999-09-01 | — | — | EP | claimed |
| WO-1998005359-A1 | CARRIER COMPOSITION FOR INFLUENCING THE TIGHT JUNCTION PERMEABILITY | GHYSSAERT, JORIS, ROSA, MICHAEL (BE) | 1998-02-12 | — | — | WO | claimed |
| EP-0821970-A1 | Carrier composition for influencing the tight junction permeability | Verhaeren, Edward Henri Charles (BE) | 1998-02-04 | — | — | EP | claimed |
| WO-1995005078-A1 | SUBMICRON EMULSIONS FOR DELIVERY OF PEPTIDES | PHARMOS CORPORATION (US) | 1995-02-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125528-A1 | Process for preparing schiff base adducts of amines with o-hydroxy aldehydes and compositions of matter based thereon | OGDH, ALDH7A1, AOX1 | AVPR1A 1970/4885AVPR1B 1040/4885AVPR2 1036/4885 |
| US-20240293345-A1 | COMBINATIONS OF LOCAL ANESTHETICS FOR IMPROVED PAIN RELIEF | OPRL1, OPRK1, OPRM1 | AVPR1A 147/4885AVPR1B 194/4885AVPR2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.